An interactive journey from DNA and protein synthesis to modern gene-editing technologies — built around the published research of Zarnigor Murodillaeva.
Based on independent literature-review researchBefore we edit genes, we need to understand the molecule that stores genetic information.
DNA stands for deoxyribonucleic acid. It stores genetic information and is built from nucleotides. The four bases are adenine (A), thymine (T), cytosine (C), and guanine (G).
In DNA, A pairs with T, while C pairs with G. Genes are segments of DNA containing information used by cells, and DNA is organized into chromosomes.
The basic information flow can be simplified as DNA → RNA → Protein.
DNA is used as a template to produce messenger RNA (mRNA). RNA uses uracil (U) instead of thymine (T), and the resulting mRNA carries genetic information toward the machinery responsible for protein production.
Ribosomes read mRNA in groups of three nucleotides called codons. Codons correspond to amino acids, which are assembled into proteins. Proteins perform many functions in cells.
Genetic alterations can include substitutions, insertions, deletions, and larger rearrangements. Some can affect normal cellular function.
Click to reveal a simple example of a single-base substitution.
The research discusses genetic disorders, cancer, sickle cell disease and mitochondrial encephalopathies as examples of health problems associated with harmful genetic changes.
Gene editing refers to technologies that enable targeted changes to DNA. It represents a more precision-oriented approach than simply adding or transferring genetic material.
Historically, genetic engineering included inserting or transferring genetic material, including recombinant DNA approaches.
Modern editing technologies are designed to make targeted changes at particular genomic locations. They use molecular targeting machinery and depend on cellular processes to complete or incorporate changes.
Precision does not mean perfection: off-target effects, delivery, efficiency, immune responses and long-term effects remain important challenges.
An interactive timeline based on the historical progression described in the research.
Recombinant DNA techniques laid groundwork for modern genetic intervention and gene-transfer strategies.
The paper describes the first successful gene-therapy treatment of a four-year-old girl with ADA-SCID.
Targeted double-strand breaks demonstrated that DNA could be modified at selected locations.
TALE repeats offered a more modular way to recognize DNA one base at a time.
A guide RNA could be changed to redirect the Cas9 complex to different DNA sequences.
Base editors enabled certain single-nucleotide conversions without conventional double-strand breaks.
Prime editing expanded the range of possible substitutions, insertions and deletions without relying on conventional double-strand breaks.
Each platform solves a slightly different problem. The key is understanding what each tool can and cannot do.
Zinc finger DNA-binding domains recognize short DNA sequences and are fused to the FokI nuclease. ZFNs function as dimers and can create targeted double-strand breaks that cells repair through pathways such as NHEJ or HDR.
Strength: foundational targeted modification.
Challenge: complex, context-dependent engineering and possible off-target effects.
TALENs use TALE repeats that recognize DNA one base at a time. They are fused to FokI and function as dimers.
Strength: modular recognition and broad targeting.
Challenge: larger, repetitive constructs can complicate delivery.
CRISPR systems originated as part of bacterial adaptive immunity. The technology became powerful because the targeting component can be retargeted by changing a small sequence in the guide RNA.
The guide RNA directs the Cas9 complex toward a complementary DNA sequence.
Changing the relevant guide sequence can redirect the complex to a different location.
CRISPR systems can support multiplexing — targeting multiple loci with multiple guides.
Off-target effects, delivery, efficiency and immune responses remain important considerations.
Instead of relying on a conventional double-strand break, base editing can make certain single-nucleotide conversions.
Cytosine base editors (CBEs) and adenine base editors (ABEs) pair a CRISPR-derived targeting component with a base-modifying enzyme.
Advantages: precise single-base changes and avoidance of conventional double-strand breaks.
Limitations: only certain substitutions are possible and the editing window is limited.
Introduced in 2019, prime editing expanded the range of changes that can be conceptually made without a conventional double-strand break.
Prime editing combines Cas9 nickase and reverse transcriptase under the direction of a specialized prime-editing guide RNA (pegRNA). The pegRNA contains information for the intended edit.
The research describes prime editing as capable of substitutions, insertions and deletions. It is more adaptable than base editing, while efficiency and delivery still require optimization.
A high-level comparison using the framing and information in the research paper.
| Feature | ZFNs | TALENs | CRISPR-Cas9 | Base Editing | Prime Editing |
|---|---|---|---|---|---|
| Targeting | Zinc-finger arrays | TALE repeats | Guide RNA | CRISPR-derived targeting | pegRNA-directed |
| Conventional DSB? | Yes | Yes | Yes | No | No conventional DSB |
| Main idea | Targeted cutting | Targeted cutting | RNA-guided cutting | Certain base conversions | Substitutions, insertions, deletions |
| Key advantage | Foundational platform | Modular DNA recognition | Retargetable and scalable | Single-base precision | Broader editing range |
| Major limitation | Complex engineering | Size/delivery | Off-target and delivery concerns | Limited substitutions/window | Efficiency/delivery still challenging |
The research reviews applications where editing may target underlying genetic or cellular problems.
Gene editing has been investigated for disorders including sickle cell disease and β-thalassemia, with the goal of addressing genetic causes rather than only symptoms.
Genome editing has been explored in cancer immunotherapy, including modification of CAR-T cells and investigation of PD-1 editing.
CCR5 disruption has been investigated as a strategy related to HIV resistance. Editing approaches have also been studied for HBV, HSV and HPV.
Patient-derived iPSCs can be conceptually corrected before differentiation into cell types such as neurons, cardiomyocytes or hepatocytes.
The research discusses proof-of-principle examples involving α-1-antitrypsin deficiency and dystrophin expression in Duchenne muscular dystrophy models.
The broader vision is increasingly individualized treatment, while safety, delivery and long-term outcomes remain central challenges.
The paper discusses a 2021 CRISPR-based clinical study involving sickle cell disease and β-thalassemia.
The promise of genome editing is substantial, but the research emphasizes that important scientific and translational obstacles remain.
Editing can potentially occur at unintended genomic locations, making specificity an ongoing concern.
Getting editing systems to the correct cells and tissues remains a major challenge.
The immune system may react to genetically altered cells or components of editing systems.
Not every target can be edited equally effectively, and long-term consequences may require continued investigation.
Responsible gene editing requires both ambition and caution.
Scientific capability does not automatically answer the question of when or how a technology should be used.
Safety · informed consent · equitable access · unintended consequences · regulation · therapeutic use versus enhancement · heritable changes
If a technology could potentially prevent a serious genetic disease, what principle should guide its use?
The research points toward technologies that could make genome editing more controllable, specific and versatile.
More effective and tissue-targeted delivery could expand therapeutic possibilities.
Different CRISPR systems, recombinases and DNA-guided nucleases may broaden the toolkit.
DNA-targeting technologies may be used to alter gene regulation or chromatin architecture without changing the DNA sequence itself.
Inducible or self-regulating mechanisms could help control expression, activity or stability of editing tools.
Researchers continue working on better ways to evaluate and improve genome-wide specificity.
Scientific progress still needs careful validation, regulation and long-term assessment.
12 questions. Immediate explanations. No laboratory coat required.
A high school student from Uzbekistan with a strong interest in molecular biology, gene editing, neuroscience, and bioengineering. My research interests focus on how advances in biotechnology can be used to understand and address biological problems.
Molecular biology
Gene editing
Bioengineering
Literature review
Genetics
Biotechnology
Science communication
Future medicine
Precision biology
By Zarnigor Murodillaeva · Volume 1(6), pp. 1–9
This literature review explores the development of gene-editing technologies from early programmable nucleases such as ZFNs and TALENs to CRISPR-Cas9, base editing and prime editing, alongside their applications, limitations and future directions.
References listed in the supplied research paper.